Table 2.

Effect of p53 pathway mutations on irradiated tumour control in the entire cohort and subsets of patients with rhabdomyosarcoma (RMS), Ewing sarcoma (ES), patients treated with palliative intent and patients treated with definitive intent (univariate analysis).

Gene	Entire cohort n = 286 (HR, 95% CI)	P	RMS n = 126 (HR, 95% CI)	P	ES n = 160 (HR, 95% CI)	P	Palliative n = 146 (HR, 95% CI)	P	Definitive n = 140 (HR, 95% CI)	P
TP53	2.8 (1.6–5.0)	<0.0001	3.8 (1.8–8.4)	0.001	1.8 (0.6–5.2)	0.27	4.0 (1.4–10.9)	0.008	3.0 (1.4–6.1)	0.004
MDM2/4	1.1 (0.4–2.6)	0.90	0.83 (0.3–2.1)	0.69	n/a	n/a	2.6 (0.6–11.2)	0.20	0.9 (0.3–3.1)	0.93
CDKN2A/B	1.3 (0.6–2.8)	0.52	0.89 (0.3–2.5)	0.81	1.1 (0.1–8.0)	0.94	0.6 (0.08–4.4)	0.61	1.9 (0.8–4.5)	0.15
Any alteration	2.0 (1.3–3.2)	0.003	1.7 (0.9–3.0)	0.10	1.6 (0.6–4.2)	0.32	2.4 (1.1–5.5)	0.04	2.4 (1.3–4.3)	0.003